InspireMD has announced that a multicentre randomised trial of its MGuard embolic protection stent demonstrated a positive outcome in treating patients suffering acute myocardial infarction when compared to commercially-approved bare metal or drug-eluting stents.
The MASTER (MGuard for acute ST elevation reperfusion) trial enrolled 433 patients in nine countries and was designed to evaluate the MGuard embolic protection stent compared to commercially-approved bare metal or drug-eluting stents in heart attack patients undergoing primary percutaneous coronary intervention (PCI).
MGuard is CE mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularisation of the European Society of Cardiology (ESC).
Plans for a US FDA registration trial are underway, with patient enrolment expected to begin by the end of 2012.
Detailed results from the MASTER trial will be presented at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting (Miami, USA, 22–26 October 2012).
About MGuard Coronary Stent
The MGuard(TM) embolic protection stent is a coronary stent integrated with a proprietary micronet technology. The micronet is designed to hold plaque and thrombus in place against the blocked artery’s wall, preventing debris from entering the bloodstream.
